Botanix Pharmaceuticals (ASX:BOT) has entered 2026 with strong commercial momentum, reporting rapid growth in prescriptions and revenue for Sofdra, its FDA-approved treatment for primary axillary hyperhidrosis, while positioning the company for improved margins and platform expansion
In the first eleven months following launch, Sofdra generated 62,500 prescriptions, $93.5 million in gross revenue and $21.2 million in net revenue, underscoring early commercial traction. The acceleration continued into the first half of the financial year 2026, with total prescriptions shipped rising 171 per cent year-on-year to 45,769. Net revenue reached $16.2 million for the half, up 219 per cent on the prior corresponding period, reflecting improved reimbursement dynamics and fulfilment execution.
Sofdra is the first and only new chemical entity approved for primary axillary hyperhidrosis, a condition affecting approximately 16.1 million people in the United States, including around 10 million with the axillary form of the disease. This patient population is more than twice the size of psoriasis in the US, reinforcing the scale of the commercial opportunity. The product works by selectively binding to M3 receptors in sweat glands to inhibit sweat production, supported by statistically significant efficacy data and a favourable safety profile.
Physician sentiment appears supportive of continued growth. Market research cited in the presentation shows that 90 per cent of surveyed healthcare professionals expect to increase their prescribing of Sofdra over the next six months. Access and fulfilment were identified as primary drivers, alongside efficacy, the proprietary applicator and safety profile.
Central to Botanix’s strategy is its proprietary fulfilment platform, which bypasses traditional wholesalers and provides integrated reimbursement support, direct-to-patient shipment, and administrative services. The company reports that the platform increases reimbursed prescriptions, supports high refill adherence, and improves gross-to-net outcomes, while operating at a fill rate 2.5 times the industry standard. Management believes this infrastructure can be leveraged to introduce new products without incremental development costs, thereby enhancing profitability and scalability.
Financially, Botanix recorded total revenue of $16.5 million for the first half, compared with $0.3 million in the prior corresponding period. Direct operating expenditure, including sales and marketing and employee costs, totalled $36.6 million, reflecting continued investment in commercial infrastructure, such as expanding the sales force to 50 representatives. The company reported an adjusted earnings loss of $26.1 million and a loss before tax of $33.2 million, consistent with a growth phase commercial rollout. Cash and cash equivalents stood at $31.6 million at period end.
To strengthen the balance sheet and support manufacturing scale-up, Botanix secured firm commitments for a $45 million capital raising. Proceeds are earmarked for active pharmaceutical ingredient purchases and manufacturing components, establishment of an alternate API supplier, marketing initiatives and working capital.
Supply chain optimisation is a key near term priority. The company is negotiating with both its current API supplier to smooth scheduled payments and with alternative suppliers to establish a second source and reduce the cost of goods sold by an estimated 25 to 40 per cent.
Looking ahead, Botanix said it identifies several catalysts for value creation, including sustained Sofdra growth, the addition of new products to the fulfilment platform, the expansion of licensing into other regions, and the realisation of manufacturing efficiencies. With patent protection extending to 2040, management believes the company is building a differentiated dermatology platform capable of delivering both near-term revenue growth and long-term strategic optionality.